Last reviewed · How we verify
polidocanol injectable foam, 0.5%
Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein.
Polidocanol works by causing endothelial damage and subsequent thrombosis in the targeted vein. Used for Treatment of varicose veins and telangiectasias.
At a glance
| Generic name | polidocanol injectable foam, 0.5% |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Drug class | sclerosing agent |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
This leads to the formation of a thrombus, which eventually closes off the vein, preventing further blood flow and alleviating symptoms of varicose veins. The exact mechanism is not fully understood, but it is thought to involve the activation of various cellular pathways and the release of pro-inflammatory mediators.
Approved indications
- Treatment of varicose veins and telangiectasias
Common side effects
- Pain
- Swelling
- Bruising
- Numbness
- Itching
Key clinical trials
- Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (PHASE3)
- Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polidocanol injectable foam, 0.5% CI brief — competitive landscape report
- polidocanol injectable foam, 0.5% updates RSS · CI watch RSS
- Boston Scientific Corporation portfolio CI